Company Quick10K Filing
Pharmacyte Biotech
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 1,258 $38
10-Q 2019-09-13 Quarter: 2019-07-31
10-K 2019-08-13 Annual: 2019-04-30
10-Q 2019-03-14 Quarter: 2019-01-31
10-Q 2018-12-14 Quarter: 2018-10-31
10-Q 2018-09-12 Quarter: 2018-07-31
10-K 2018-07-20 Annual: 2018-04-30
10-Q 2018-03-19 Quarter: 2018-01-31
10-Q 2017-12-14 Quarter: 2017-10-31
10-Q 2017-09-13 Quarter: 2017-07-31
10-K 2017-07-27 Annual: 2017-04-30
10-Q 2017-03-13 Quarter: 2017-01-31
10-Q 2016-12-02 Quarter: 2016-10-31
10-Q 2016-09-06 Quarter: 2016-07-31
10-K 2016-07-29 Annual: 2016-04-30
10-Q 2016-03-08 Quarter: 2016-01-31
10-Q 2015-12-10 Quarter: 2015-10-31
10-Q 2015-08-25 Quarter: 2015-07-31
10-K 2015-07-29 Annual: 2015-04-30
10-Q 2015-03-13 Quarter: 2015-01-31
10-Q 2014-12-15 Quarter: 2014-10-31
10-Q 2014-09-15 Quarter: 2014-07-31
10-K 2014-08-04 Annual: 2014-04-30
10-Q 2014-03-17 Quarter: 2014-01-31
10-Q 2013-12-16 Quarter: 2013-10-31
10-Q 2013-09-16 Quarter: 2013-07-31
10-K 2013-07-29 Annual: 2013-04-30
10-Q 2013-03-26 Quarter: 2013-01-31
10-Q 2012-12-26 Quarter: 2012-10-31
10-Q 2012-09-19 Quarter: 2012-07-31
10-K 2012-08-14 Annual: 2012-04-30
10-Q 2012-03-21 Quarter: 2012-01-31
10-Q 2011-12-15 Quarter: 2011-10-31
10-Q 2011-09-19 Quarter: 2011-07-31
10-K 2011-08-15 Annual: 2011-04-30
10-Q 2011-03-08 Quarter: 2011-01-31
10-Q 2011-01-28 Quarter: 2010-10-31
10-Q 2011-01-14 Quarter: 2010-07-31
10-K 2010-12-29 Annual: 2010-04-30
10-Q 2010-03-22 Quarter: 2010-01-31
8-K 2019-11-07 Amend Bylaw, Exhibits
8-K 2019-09-20 Amend Bylaw, Exhibits
8-K 2019-08-23 Other Events, Exhibits
8-K 2018-05-14 Exhibits
8-K 2018-02-22 Enter Agreement, Leave Agreement, Exhibits

Pharmacyte Biotech Financials

PMCB Metrics, Comps, Filings

Annual | Quarterly

Business

We are a clinical stage biotechnology company focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable non-metastatic pancreatic cancer (“LAPC”) and Type 1 and insulin dependent Type 2 diabetes will be developed.

We are developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells that are capable of converting a cancer prodrug into its cancer-killing form, encapsulating those cells using the Cell-in-a-Box® technology and placing those capsules in the body as close as possible to the tumor. In this way, when the cancer prodrug is administered to a patient with a particular type of cancer that may be affected by the prodrug, the killing of the patient's tumor may be optimized.

We are also examining ways to exploit the benefits of the Cell-in-a-Box® technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant; these constituents are of the class of compounds known as “cannabinoids”.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Earth Science Tech (ETST) 39,246 53% -19.3 -600% 352 833 597 316 -2,113 -2,030 39,211
Cipherloc (CLOK) 38,753 85% -5.5 -43% 11,652 186 87 74 -5,012 -5,029 27,662
First Choice Healthcare Solutions (FCHS) 38,514 16.2 3% 27,801 7,984 0 0 832 1,917 31,130
Echelon (ELON) 38,425 55% -8.2 -17% 28,010 6,437 31,601 17,474 -4,655 -4,090 33,505
Protagenic (PTIX) 38,275 -17.0 -640% 350 729 0 0 -2,237 -2,237 37,936
Williams Industrial Services Group (WLMS) 37,976 14% -6.6 -11% 103,066 81,820 219,940 31,418 -11,645 -10,787 71,308
Pharmacyte Biotech (PMCB) 37,745 -11.8 -57% 5,606 607 0 0 -3,171 -3,170 37,417
Invesco DB US Dollar Index Bearish Fund (UDN) 37,692 -48.5 -2% 41,690 4,002 0 0 -780 -778 37,692
Leafbuyer (LBUY) 36,895 109% -5.1 -175% 3,915 3,279 1,892 2,064 -6,835 -7,160 36,713
Xplore Technologies (XPLR) 36,845 30% 14.6 0% 63,578 33,303 86,852 25,892 300 2,519 36,799
Cannabis Sativa (CBDS) 36,574 52% -16.5 -59% 4,489 2,699 454 238 -2,665 -2,219 36,514
Exeo Entertainment (EXEO) 36,179 39% -32.7 -146% 761 1,762 127 49 -1,113 -1,104 36,043
Exactus (EXDI) 35,907 26% -8.0 -81% 6,426 2,224 156 40 -5,221 -4,410 35,343
Darkpulse (KLMK) 35,876 -25.8 -397% 584 3,359 0 0 -2,320 -1,432 36,998
Equitable Financial (EQFN) 35,831 -0.0 0% 305,668 269,015 0 0 571 3,492 -156
FoodFirst (BBRG) 35,805 0% 31.4 -11% 133,876 166,149 398,247 0 -15,391 2,421 76,068
BLOX (BLXX) 35,706 -3.1 -932% 1,250 622 0 0 -11,649 -11,649 35,697
Western Capital Resources (WCRS) 35,677 56% -0.9 1% 89,005 23,300 114,140 64,322 1,043 4,438 -4,095
Innovation Pharmaceuticals (IPIX) 35,645 -4.5 -205% 4,046 8,175 0 0 -8,282 -7,859 35,066
Medicine Man Technologies (MDCL) 35,582 57% -2.9 -51% 21,365 7,738 10,550 6,041 -10,993 -10,916 31,234

Balance Sheet ($'000)2012-04-302013-04-302014-04-302015-04-302016-04-302017-04-302018-04-302019-04-30
Cash161993,6162,7001,9213,4641,060515
Accounts Receivable30
Inventory70
PP&E0
Assets2,0882,8779,3167,9487,1608,6676,4135,782
Accounts Payable730352188497336366353122
Long-Term Debt20
Liabilities3,7873,7983742,012638580644743
Stockholders' Equity-2,280-1,5018,9425,9366,5238,0875,7695,040
Income Statement ($'000)2012-04-302013-04-302014-04-302015-04-302016-04-302017-04-302018-04-302019-04-30
Revenue6712000000
Cost of Revenue1910000
Gross Profit473000
R&D3,4771,4071,1821,998460
SG&A4277243,1132,8272,2917451,8191,379
Tax0000001
Net Income-1,899-1,598-27,254-10,855-6,064-4,444-6,829-4,067
Cash Flow ($'000)2012-04-302013-04-302014-04-302015-04-302016-04-302017-04-302018-04-302019-04-30
Cash Operating-259-390-1,563-4,560-4,346-3,339-5,079-2,878
Cash Investing-872-647-3,55100000
Cash Financing1,0901,2218,5313,6423,5684,8822,6812,342